These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 37456249)
1. Differentiating malignant and benign pleural effusion in patients with lung cancer: an Zhang W; Liu Z; Duan X; Li Y; Shen C; Guo Y; Yang J Front Oncol; 2023; 13():1192870. PubMed ID: 37456249 [TBL] [Abstract][Full Text] [Related]
2. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients. Kim BS; Kim IJ; Kim SJ; Pak K; Kim K Onkologie; 2011; 34(6):298-303. PubMed ID: 21625182 [TBL] [Abstract][Full Text] [Related]
3. Development and validation of the PET-CT score for diagnosis of malignant pleural effusion. Yang MF; Tong ZH; Wang Z; Zhang YY; Xu LL; Wang XJ; Li W; Wu XZ; Wang W; Zhang YH; Jiang T; Shi HZ Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1457-1467. PubMed ID: 30903197 [TBL] [Abstract][Full Text] [Related]
4. Can PET/CT be used more effectively in pleural effusion evaluation? Simsek FS; Yuksel D; Yaylali O; Aslan HS; Kılıçarslan E; Bir F; Arslan M; Can FE; Ugurlu E Jpn J Radiol; 2021 Dec; 39(12):1186-1194. PubMed ID: 34165683 [TBL] [Abstract][Full Text] [Related]
5. Lymph nodes rather than pleural metabolic activity in Jiang Y; Liu T; Xu K; Cheng Q; Lu W; Xie J; Chen M; Li Y; Du Y; Liang S; Song Y; Wu J; Lv T; Zhan P Transl Lung Cancer Res; 2024 Sep; 13(9):2236-2253. PubMed ID: 39430341 [TBL] [Abstract][Full Text] [Related]
6. [Clinical role of F-18 FDG PET/CT in differentiating malignant and benign pleural effusion in patients with lung cancer]. Liao R; Yang X; Wang S; Zhou Q; Nie Q; Zhong W; Dong S; Wu Y Zhongguo Fei Ai Za Zhi; 2012 Nov; 15(11):652-5. PubMed ID: 23164351 [TBL] [Abstract][Full Text] [Related]
7. The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion. Sun Y; Yu H; Ma J; Lu P PLoS One; 2016; 11(8):e0161764. PubMed ID: 27560933 [TBL] [Abstract][Full Text] [Related]
8. Predicting the nature of pleural effusion in patients with lung adenocarcinoma based on Li Y; Mu W; Li Y; Song X; Huang Y; Jiang L EJNMMI Res; 2021 Oct; 11(1):108. PubMed ID: 34652524 [TBL] [Abstract][Full Text] [Related]
9. [Value of PET/MRI in the diagnosis of malignant pleural effusion in comparison with PET/CT]. Peng WB; Sun X; Zhou M; Wei XS; Wu XZ; Ruan WW; Shi HZ; Lan XL; Zhou Q Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2363-2369. PubMed ID: 34404128 [No Abstract] [Full Text] [Related]
10. Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study. Fan X; Liu Y; Liang Z; Wang S; Yang J; Wu A Pathol Oncol Res; 2022; 28():1610280. PubMed ID: 35515016 [No Abstract] [Full Text] [Related]
11. Dynamic FDG-PET imaging for differentiating metastatic from non-metastatic lymph nodes of lung cancer. Wumener X; Zhang Y; Wang Z; Zhang M; Zang Z; Huang B; Liu M; Huang S; Huang Y; Wang P; Liang Y; Sun T Front Oncol; 2022; 12():1005924. PubMed ID: 36439506 [TBL] [Abstract][Full Text] [Related]
12. The contribution of PET/CT to the differentiation of benign and malignant pleural effusion in patients with ovarian carcinoma. Budak A; Yanarateş A; Budak E Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(6):353-358. PubMed ID: 37172933 [TBL] [Abstract][Full Text] [Related]
13. The value on SUV-derived parameters assessed on Liao X; Liu M; Li S; Huang W; Guo C; Liu J; Xiong Y; Zhang J; Fan Y; Wang R BMC Med Imaging; 2023 Apr; 23(1):49. PubMed ID: 37020286 [TBL] [Abstract][Full Text] [Related]
14. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Gupta NC; Rogers JS; Graeber GM; Gregory JL; Waheed U; Mullet D; Atkins M Chest; 2002 Dec; 122(6):1918-24. PubMed ID: 12475827 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the assessment of pleural abnormalities in cancer patients: a systematic review and a meta-analysis. Treglia G; Sadeghi R; Annunziata S; Lococo F; Cafarotti S; Prior JO; Bertagna F; Ceriani L; Giovanella L Lung Cancer; 2014 Jan; 83(1):1-7. PubMed ID: 24290256 [TBL] [Abstract][Full Text] [Related]
16. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes. Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845 [TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer. Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680 [TBL] [Abstract][Full Text] [Related]
19. Value of human epididymis secretory protein 4 in differentiating malignant from benign pleural effusion: an analysis of two cohorts. Yang Q; Niu Y; Wen JX; Yang DN; Han YL; Wen XH; Yan L; Huang JH; Chen H; Zheng WQ; Jiang TW; Hu ZD Ther Adv Respir Dis; 2023; 17():17534666231216566. PubMed ID: 38084849 [TBL] [Abstract][Full Text] [Related]
20. The diagnostic ability of Lee JW; Kim EY; Kim DJ; Lee JH; Kang WJ; Lee JD; Yun M Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]